Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation

Leukemia

Volumn 19, Issue 4, 2005, Pages 500-503

  Mohty, M ^a,b   Faucher, C ^a   Blaise, D ^a,b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE PAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HOSPITALIZATION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LENGTH OF STAY; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEM CELL MOBILIZATION; SURVIVAL RATE; T LYMPHOCYTE;

EID: 17144386239     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403660     Document Type: Article

References (57)

1. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
2. Caspar CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-2871.
3. Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Law P et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-646.
4. Tanaka J, Imamura M, Zhu X, Kobayashi S, Imai K, Hashino S et al. Potential benefit of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994; 84: 3595-3596.
5. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
6. Korbling M, Przepiorka D, Gajewski J, Champlin RE, Chan KW. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood 1995; 86: 1235.
7. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
8. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
9. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
10. Russell JA, Luider J, Weaver M, Brown C, Selinger S, Railton C et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15: 111-115.
11. Azevedo WM, Aranha FJ, Gouvea JV, Vigorito AC, Marques Jr JF, Eid KA et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-653.
12. Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003; 17: 941-959.
13. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft versus host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128-3134.
14. Kitayama H, Ishikawa J, Yamagami T, Teshima H, Hiraoka A, Nakamura H et al. Granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Jpn J Clin Oncol 1989; 19: 367-372.
15. Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A et al. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 1989; 17: 1047-1050.
16. Asano S, Masaoka T, Takaku F. Clinical effect of recombinant human granulocyte colony-stimulating factor in bone marrow transplantation - The Japan rhG-CSF Clinical Study Group. Gan To Kagaku Ryoho 1990; 17: 1201-1209.
17. De Witte T, Gratwohl A, Van Der Lely N, Bacigalupo A, Stern AC, Speck B et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359-1365.
18. Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-1420.
19. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680-1684.
20. Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700.
21. Hiraoka A, Masaoka T, Mizoguchi H, Asano S, Kodera Y, Kitamura K et al. Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Jpn J Clin Oncol 1994; 24: 205-211.
22. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949-954.
23. Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Exp Hematol 1995; 23: 1503-1508.
24. Locatelli F, Pession A, Zecca M, Bonetti F, Prete L, Carra AM et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996; 17: 31-37.
25. Saarinen UM, Hovi L, Juvonen E, Riikonen P, Mottonen M, Makipernaa A. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Pediatr Oncol 1996; 26: 380-386.
26. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294-1299.
27. Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R et al. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 1999; 23: 983-990.
28. Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999; 84: 133-137.
29. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 663-666.
30. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-85.
31. Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405-3410.
32. Ozcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, Ilhan O et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: 499-505.
33. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423.
34. Meyers JD, Atkinson K. Infection in bone marrow transplantation. Clin Haematol 1983; 12: 791-811.
35. Zimmerli W, Zarth A, Gratwohl A, Speck B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood 1991; 77: 393-399.
36. Teshima H, Ishikawa J, Kitayama H, Yamagami T, Hiraoka A, Nakamura H et al. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study. Exp Hematol 1989; 17: 853-858.
37. Asano S, Masaoka T, Takaku F. Beneficial effect of recombinant human glycosylated granulocyte colony-stimulating factor in marrow-transplanted patients: results of multicenter phase II-III studies. Transplant Proc 1991; 23 (Part 2): 1701-1703.
38. Lickliter JD, Roberts AW, Grigg AP. Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. Aust N Z J Med 1994; 24: 541-546.
39. Linch DC, Scarffe H, Proctor S, Chopra R, Taylor PR, Morgenstern G et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
40. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819-2825.
41. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998; 5: 221-225.
42. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998; 92: 215-222.
43. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
44. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
45. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
46. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-2274.
47. Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299-306.
48. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771-775.
49. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217-223.
50. Dallorso S, Rondelli R, Messina C, Pession A, Giorgiani G, Fagioli F et al. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica 2002; 87: 1274-1280.
51. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FRJ, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; Nov 1 [E-pub ahead of print].
52. Kobayashi S, Imamura M, Hashino S, Noto S, Mori A, Tanaka J et al. Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. Leuk Lymphoma 1999; 33 559-566.
53. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514-2521.
54. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
55. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476.
56. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
57. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.